4.7 Article

Occult axillary node metastases in breast cancer are prognostically significant: Results in 368 node-negative patients with 20-year follow-up

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 26, Issue 11, Pages 1803-1809

Publisher

AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2007.12.6425

Keywords

-

Categories

Ask authors/readers for more resources

Purpose In breast cancer, sentinel lymph node (SLN) biopsy allows the routine performance of serial sections and/or immunohistochemical (IHC) staining to detect occult metastases missed by conventional techniques. However, there is no consensus regarding the optimal method for pathologic examination of SLN, or the prognostic significance of SLN micrometastases. Patients and Methods In 368 patients with axillary node-negative invasive breast cancer, treated between 1976 and 1978 by mastectomy, axillary dissection, and no systemic therapy, we reexamined the axillary tissue blocks following our current pathologic protocol for SLN. Occult lymph node metastases were categorized by pattern of staining (immunohistochemically positive or negative [IHC +/-], hematoxylin-eosin staining positive or negative [H&E±]), number of positive nodes (0, 1, > 1), number of metastatic cells (0, 1 to 20, 21 to 100, > 100), and largest cluster size (<= 0.2 mm [pN0(i+)], 0.3 to 2.0 mm [pN1(mi)], > 2.0 mm [pN1a]). We report 20-year results as overall survival (OS), disease-free survival (DFS), and disease-specific death (DSD). Results A total of 23% of patients (83 of 368) were converted to node-positive. Of these, 73% were <= 0.2 mm in size (pN0(i+)), 20% were 0.3 to 2.0 mm (pN1(mi)), and 6% were more than 2 mm (pN1a). On univariate and multivariate analysis, pattern of staining, number of positive nodes, number of metastatic cells, and cluster size were all significantly related to both DFS and DSD. On multivariate analysis, each of these measures had significance comparable to, or greater than, tumor size, grade or lymphovascular invasion. Conclusion In breast cancer patients staged node-negative by conventional single-section pathology, occult axillary node metastases detected by our current pathologic protocol for SLN are prognostically significant.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Retraction Biochemistry & Molecular Biology

撤稿声明: Withdrawal: Cyclooxygenase-2-derived prostaglandin E2 stimulates Id-1 transcription (Retraction of Vol 283, Pg 33955, 2008)

Kotha Subbaramaiah, Robert Benezra, Clifford Hudis, Andrew J. Dannenberg

JOURNAL OF BIOLOGICAL CHEMISTRY (2020)

Retraction Biochemistry & Molecular Biology

撤稿声明: Withdrawal: EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells: Evidence of a BRCA1 and p300 exchange (Retraction of Vol 283, Pg 33955, 2008)

Kotha Subbaramaiah, Clifford Hudis, Sung-Hee Chang, Timothy Hla, Andrew J. Dannenberg

JOURNAL OF BIOLOGICAL CHEMISTRY (2020)

Article Oncology

Discrepancies in Financial Self-Disclosures and Open Payments Reporting Among Authors of Clinical Oncology Research Studies

Elizabeth Garrett-Mayer, Melinda W. Kaltenbaugh, Rebecca Spence, Suanna S. Bruinooge, Clifford A. Hudis, Dina Michels, Richard L. Schilsky

JOURNAL OF CLINICAL ONCOLOGY (2020)

Article Oncology

First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer

Mark P. S. Dunphy, Christina Pressl, Nagavarakishore Pillarsetty, Milan Grkovski, Shanu Modi, Komal Jhaveri, Larry Norton, Bradley J. Beattie, Pat B. Zanzonico, Danuta Zatorska, Tony Taldone, Stefan O. Ochiana, Mohammad M. Uddin, Eva M. Burnazi, Serge K. Lyashchenko, Clifford A. Hudis, Jacqueline Bromberg, Heiko M. Schoder, Josef J. Fox, Hanwen Zhang, Gabriela Chiosis, Jason S. Lewis, Steven M. Larson

CLINICAL CANCER RESEARCH (2020)

Article Oncology

Bridging the Gap Among Clinical Practice Guidelines for Pain Management in Cancer and Sickle Cell Disease

Alyssa A. Schatz, Thomas K. Oliver, Robert A. Swarm, Judith A. Paice, Deepika S. Darbari, Deborah Dowell, Salimah H. Meghani, Katy Winckworth-Prejsnar, Eduardo Bruera, Robert M. Plovnick, Lisa Richardson, Neha Vapiwala, Dana Wollins, Clifford A. Hudis, Robert W. Carlson

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)

Article Oncology

Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy

Mark Jesus M. Magbanua, Laura H. Hendrix, Terry Hyslop, William T. Barry, Eric P. Winer, Clifford Hudis, Deborah Toppmeyer, Lisa Anne Carey, Ann H. Partridge, Jean-Yves Pierga, Tanja Fehm, Jose Vidal-Martinez, Dimitrios Mavroudis, Jose A. Garcia-Saenz, Justin Stebbing, Paola Gazzaniga, Luis Manso, Rita Zamarchi, Maria Luisa Antelo, Leticia De Mattos-Arruda, Daniele Generali, Carlos Caldas, Elisabetta Munzone, Luc Dirix, Amy L. Delson, Harold J. Burstein, Misbah Qadir, Cynthia Ma, Janet H. Scott, Francois-Clement Bidard, John W. Park, Hope S. Rugo

Summary: This study identified 4 novel prognostic groups in metastatic breast cancer (MBC) based on similarities in circulating tumor cell (CTC) trajectory patterns during chemotherapy. Patients with intermediate+high CTCs (19.4%) had significantly poorer outcomes and may benefit from more effective treatment. This novel prognostic classification approach may guide future prospective clinical trials in MBC.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

Retraction Oncology

撤稿声明: Increased Levels of COX-2 and Prostaglandin E2 Contribute to Elevated Aromatase Expression in Inflamed Breast Tissue of Obese Women (Retraction of Vol 2, Pg 356, 2012)

Kotha Subbaramaiah, Patrick G. Morris, Xi Kathy Zhou, Monica Morrow, Baoheng Du, Dilip Giri, Levy Kopelovich, Clifford A. Hudis, Andrew J. Dannenberg

CANCER DISCOVERY (2021)

Article Oncology

Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance)

Jennifer A. Ligibel, Luke Huebner, Hope S. Rugo, Harold J. Burstein, Debra L. Toppmeyer, Carey K. Anders, Cynthia Ma, William T. Barry, Vera Suman, Lisa A. Carey, Ann H. Partridge, Clifford A. Hudis, Eric P. Winer

Summary: In metastatic breast cancer patients, high rates of obesity and inactivity were observed, but they were not significantly associated with PFS and OS. Greater than 9 MET hours of PA per week may be marginally associated with improved PFS and OS outcomes.

JNCI CANCER SPECTRUM (2021)

Meeting Abstract Oncology

Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106)

Cynthia X. Ma, Vera Suman, A. Marilyn Leitch, Souzan Sanati, Kiran Vij, Gary W. Unzeitig, Jeremy Hoog, Mark Watson, Olwen Hahn, Joseph Guenther, Abigail Caudle, Erika Crouch, Horacio Maluf, Amy Tiersten, Monica Mita, Wajeeha Razaq, Tina J. Hieken, Yang Wang, Travis Dockter, Jo Anne Zujewski, Anna Weiss, Kelly Hunt, Clifford Hudis, Eric P. Winer, Matthew J. Ellis, Lisa A. Carey, Ann H. Partridge

CANCER RESEARCH (2021)

Meeting Abstract Oncology

Validation of a predictive model for potential response to neoadjuvant endocrine therapy ( NET) in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC): An ALTERNATE trial analysis (Alliance A011106)

Matthew J. Ellis, Vera Suman, A. Marilyn Leitch, Souzan Sanati, Kiran Vij, Gary W. Unzeitig, Jeremy Hoog, Mark Watson, Olwen Hahn, Joseph Guenther, Abigail Caudle, Erika Crouch, Horacio Maluf, Mitch Dowsett, Amy Tiersten, Monica Mita, Wajeeha Razaq, Tina J. Hieken, Yang Wang, Travis Dockter, Jo Anne Zujewski, Anna Weiss, Clifford Hudis, Eric P. Winer, Kelly Hunt, Ann H. Partridge, Cynthia X. Ma, Lisa A. Carey

CANCER RESEARCH (2021)

Letter Oncology

Reply to M. Hutton-Potts and AM Joshua

Clifford A. Hudis, Richard L. Schilsky

JCO ONCOLOGY PRACTICE (2020)

Article Oncology

Bridging the Gap Among Clinical Practice Guidelines for Pain Management in Cancer and Sickle Cell Disease

Alyssa A. Schatz, Thomas K. Oliver, Robert A. Swarm, Judith A. Paice, Deepika S. Darbari, Deborah Dowell, Salimah H. Meghani, Katy Winckworth-Prejsnar, Eduardo Bruera, Robert M. Plovnick, Lisa Richardson, Neha Vapiwala, Dana Wollins, Clifford A. Hudis, Robert W. Carlson

JCO ONCOLOGY PRACTICE (2020)

Meeting Abstract Oncology

ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or Ill estrogen receptor-positive HER2-negative breast cancer (ER+HER2-BC) in postmenopausal (PM) women: Alliance A011106.

Cynthia X. Ma, Vera J. Suman, A. Marilyn Leitch, Souzan Sanati, Kiran R. Vij, Gary Walter Unzeitig, Jeremy Hoog, Mark Watson, Olwen Mary Hahn, J. Michael Guenther, Abigail Suzanne Caudle, Travis Dockter, Larissa A. Korde, Anna Weiss, Kelly Hunt, Clifford A. Hudis, Eric P. Winer, Ann H. Partridge, Lisa A. Carey, Matthew James Ellis

JOURNAL OF CLINICAL ONCOLOGY (2020)

Article Oncology

Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors

Pedram Razavi, Maura N. Dickler, Payal D. Shah, Weiyi Toy, David N. Brown, Helen H. Won, Bob T. Li, Ronglai Shen, Neil Vasan, Shanu Modi, Komal Jhaveri, Betty Ann Caravella, Sujata Patil, Pier Selenica, Stephen Zamora, Aimee M. Cowan, Elizabeth Comen, Andy Singh, Anne Covey, Michael F. Berger, Clifford A. Hudis, Larry Norton, Rebecca J. Nagy, Justin I. Odegaard, Richard B. Lanman, David B. Solit, Mark E. Robson, Mario E. Lacouture, Edi Brogi, Jorge S. Reis-Filho, Mary Ellen Moynahan, Maurizio Scaltriti, Sarat Chandarlapaty

NATURE CANCER (2020)

No Data Available